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ANALYSIS OF THE ASSOCIATION BETWEEN POLYMORPHISM IN 
DHFR AND SLC19A1 GENES, CLINICAL FACTORS AND 
METHOTREXATE-RELATED SIDE EFFECTS IN RHEUMATOID 
ARTHRITIS PATIETS FROM HUSM, KELANTAN. 
 
ABSTRACT 
 
Methotrexate (MTX) is folic acid antagonist that widely used for treatment of 
rheumatoid arthritis (RA) nowadays. Despite its proven efficacy in RA patients, the 
occurrence of adverse effects is a major reason for drug discontinuation. Generally, 
more than 30% of patients on MTX are susceptible to risk of MTX-related adverse 
effects (AEs) in which 19% of them had discontinued the drug. In clinical setting, it 
is currently challenging to predict which patients on MTX are possibly developing 
drug toxicity. Most studies speculate demographic characteristics and clinical factors 
are associated with risk of MTX-related AEs. Besides that, the genetic 
polymorphisms in the folate pathway are also implicated in MTX outcome. Two 
single nucleotide polymorphisms (SNPs) in dihydrofolate reductase (DHFR) (i.e; 
rs12517451) and solute carrier family 19 folate transporter member 1, SLC19A1 (i.e: 
rs1050266) genes were reported as promising predictive genetic markers for MTX 
toxicity. Until now, no genetic association study among Malaysian population has 
explored the influence of both SNPs on MTX toxicity.  Therefore, we aim to study 
the association of SLC19A1 rs1051266 and DHFR rs12517451 variants, together 
with other clinical factors on MTX-related AEs among RA patients from HUSM, 
Kelantan. This is a case-control study, and involves 72 RA patients, 27 patients were 
assigned as cases and 45 patients were classified as control. All information 
regarding demographics and clinical characteristics of patients were obtained through 
examination of patient’s medical records. The genotyping of selected archived DNA 
xiv 
 
samples of RA samples were performed by using PCR-RFLP (Polymerase Chain 
Reaction-Restriction Fragment Length Polymorphism) technique and followed by 
sequencing. The results indicated that, the most frequent MTX toxicity was 
Gastrointestinal (GI) toxicity (37%), followed by haematological toxicity (29.6%), 
skin toxicity (18.5%), pulmonary toxicity (14.8%), fatigue (11.1%) and only one 
patient with elevated liver enzyme level was identified. The results also indicated 
that there were no difference in demographic variables and clinical factors analysed 
between cases and controls. Besides that, no significant different in the genotype and 
allele frequencies for both DHFR rs12517451 and SLC19A1 rs1051266 variant 
between cases and controls was found suggesting that both SNPs were not associated 
to the risk of MTX-related AEs. Due to small sample size, our finding warrant 
further investigation and replication in larger patient cohort and in multicentre trials.  
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Analisis perkaitan di antara polimorfik dalam gen DHFR dan SLC19A1, faktor 
klinikal dan kesan buruk Methotrexate dalam kalangan pesakit rheumatoid 
arthritis dari HUSM, Kelantan. 
 
ABSTRAK 
 
Methotrexate (MTX) adalah antagonis asid folat yang digunakan secara meluas bagi 
rawatan rheumatoid arthritis (RA) pada masa kini. Walaupun telah terbukti 
keberkesanannya, kesan buruk MTX adalah penyebab utama pesakit diberhentikan 
daripada rawatan. Secara amnya, lebih daripada 30% pesakit mengambil MTX 
terdedah kepada risiko kesan buruk terkait dengan MTX, di mana 19% daripada 
mereka berhenti mengambil MTX. Dalam aturan klinikal, pada masa ini, amatlah 
sukar untuk kita mengenal pasti pesakit yang terdedah kepada kesan buruk berkaitan 
MTX. Kebanyakan kajian mencadangkan karekter demografi pesakit dan faktor 
klinikal berhubung kait dengan risiko mendapatkan kesan buruk MTX. Selain itu, 
polimorfisme nukleotid tunggal (SNPs) dalam dihydrofolate reductase (DHFR) 
(rs12517451) dan solute carrier family 19 folate transporter member 1, SLC19A1 
(rs1050266) telah dilaporkan sebagai penanda genetik bagi mengenal pasti kesan 
buruk MTX. Sehingga kini, tiada kajian genetik kaitan hubungan di antara kedua-dua 
SNPs tersebut dan kesan toksik MTX dalam kalangan penduduk Malaysia. Oleh itu, 
tujuan kajian ini adalah mengkaji perkaitan di antara varian SLC19A1 rs1051266 dan 
DHFR rs12517451, bersama faktor klinikal lain keatas kesan buruk MTX, dalam 
kalangan pesakit RA dari HUSM, Kelantan. Ini adalah kajian kes-kawalan yang 
melibatkan 72 pesakit RA, dimana 27 pesakit dikategorikan sebagai kes manakala 45 
pesakit dikategorikan sebagai kawalan. Kesemua maklumat mengenai demografi dan 
ciri  klinikal pesakit diperolehi melalui pemeriksaan rekod perubatan pesakit. Kaedah 
genotip sampel DNA arkib telah dilakukan menggunakan teknik PCR-RFLP 
xvi 
 
(Polymerase Reaction-Restriction Fragment Length Polymorphism) dan diikuti 
dengan penjujukan DNA. Keputusan menunjukkan, kesan toksik MTX paling kerap 
ialah gastrousus(GI) (37%), diikuti dengan kesan toksik hematologi (26.9%), kesan 
toksik kulit (18.5%), ketoksikan paru-paru (14.8%), keletihan (11.1%), dan hanya 
seorang pesakit mengalami kenaikan tahap enzim hati dikesan. Keputusan juga 
menunjukkan bahawa tiada perbezaan bagi demografi dan faktor klinikal yang 
dianalisis di antara kes dan kawalan. Selain itu, tiada perkaitan yang dikenal pasti 
bagi taburan genotip dan alel kedua-dua varian DHFR rs12517451 dan SLC19A1 
1051266 yang dianalisis di antara kes dan kawalan. Ini mencadangkan bahawa 
kedua-dua SNPs tidak mempunyai perkaitan dengan risiko kesan buruk MTX. Oleh 
kerana saiz sampel yang kecil, hasil kajian ini boleh disyorkan untuk dikaji selidik 
dalam kajian susulan yang mempunyai saiz sampel pesakit yang lebih besar dan 
melibatkan banyak lokasi penyelidikan (multicentre). 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Introduction 
 
Rheumatoid arthritis (RA) is a multi-systemic autoimmune disorder characterized by 
chronic synovial joint inflammation which leads to disability and irreversible damage 
as well as limited mobility (Atic, Muralidharan and Jain, 2016). Nowadays, it is 
estimated to affect 1-5% of worldwide population (Atic, Muralidharan and Jain, 
2016). According to Global Burden of Disease 2010 study regarding burden of RA, 
the prevalence of RA is the highest in the Australasian region followed by Western 
Europe and North America (high-income population), whereby the lowest is in Asia 
(East and Southeast region) and North Africa/Middle East. RA is listed at 42
nd
 of the 
highest contributor among disabilities disorders to global disability (Cross et al., 
2014). It is also known that the risk of RA is associated with both genetic and 
environmental factors (Ramamoorthy, Abraham and Isaac, 2014). Frequently, RA is 
diagnosed among middle-aged adults and incidence is two times higher in females 
compared to males (Cross et al., 2014). The detection of RA at an early stage of 
disease to receive appropriate intervention is crucial to a good prognosis.  
 
Several types of Disease Modifying Antirheumatic Drugs (DMARDs) have been 
used for treatment of RA, but methotrexate (MTX) is the first-line treatment because 
of its established efficacy and affordability (Owen et al., 2012). MTX is an 
antimetabolite agent that specifically inhibits dihydrofolate reductase (DHFR) 
activity and also some other enzymes and leads to suppression of cell growth. It is 
also generally used for treatment of other chronic inflammatory disorders such as 
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psoriasis, systemic lupus erythematosus (SLE) and various malignancies. Initially, 
MTX was introduced as an anticancer agent and then started being used as primary 
treatment for RA after it was discovered effectively improved disease activity in RA 
patient. Besides, a large scale study also found more than 75% RA patients went into 
remission after receiving 7.5-mg/week of MTX (Buhroo and Ortho, 2006). 
 
Currently, the literature regarding the mechanism of MTX was still scarce. It is well 
known that, MTX is an active drug that is a highly selective competitive inhibitor of 
dihydrofolate reductase that converts dihydrofolate to tetrahydrofolate (THF), which 
is an important precursor for biologically active folate cofactors. MTX mainly enter 
cells by an active transport mechanism via the reduced folate carrier (RFC). Within 
the cell, MTX is activated into polyglutamate form of MTX (MTX-PG) by the 
enzyme folypolyglutamate synthase (FPGS). MTX-PG can be hydrolysed by the 
enzyme γ-glutamyl hydrolase (GGH) and transported out cells by ABC protein 
transport. MTX-PG also inhibits dihydrofolate reductase (DHFR) together with 
thymidylate synthase (TYMS) and 5-aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) transformylase (ATIC). This results in increasing intracellular adenosine 
levels which appears to be the mechanism for the anti-inflammatory activity of 
methotrexate (Stamp and Roberts, 2011). 
 
Despite its proven efficacy in RA patients, the outcome of MTX treatment is 
unpredictable. Interpatient variability in response to treatment may be associated 
with several factors such as demographic factors (age and sex), disease specific 
factors (disease duration and severity) as well as other factors such as concomitant 
drugs, folic acid supplementation and genetic variation. Number of studies have 
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demonstrated some of these factors affect both efficacy and toxicity of MTX in RA 
patients (Owen et al., 2012; Wessels et al., 2006). Furthermore, despite the 
complexity of MTX response among RA patients, there is still no available test to 
predict the treatment outcome. Current routine tests such as blood and liver function 
testing are relatively costly and regular checking of patients using these tests is 
inconvenient and burdensome (Owen et al., 2012). 
 
Even though MTX is relatively effective compared to other DMARDs, the presence 
of side effects is a major factor in discontinuation of treatment rather than lack of 
efficacy. The most common side effects experienced by RA patients including 
gastrointestinal intolerance, hepatotoxicity, pancytopenia, alopecia and sometimes 
unexpected pulmonary and bone marrow toxicity. Approximately 30% of RA 
patients treated with low dosage of MTX having side effects after at least 6 months 
treatment duration (Li et al., 2016). Commonly, those who experiences MTX-related 
side effects either withdraw from MTX therapy or are change to other available 
DMARDs with good safety profiles. Alternatively, MTX-related side effects will be 
resolved after reducing the MTX dosage to fit to patient conditions. Besides that, 
folic acid supplementation can alleviate the side effects due to folate deficiency 
without interfering with the therapeutic activity of MTX in RA patients (Buhroo and 
Ortho, 2006). 
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1.2 The Significant of Study and Contribution in Clinical Setting 
This study is relevant to be conducted in order to provide a data regarding the 
prevalence and incidence of MTX-related adverse effects in RA patients specifically 
among our population. To date, limited data and evidence describing the occurrence 
of MTX toxicity in our population.  Since MTX has been prescribed as the first line 
treatment for most RA patients, the major concerns about the risk of side effects 
become the main issues in clinical setting.  
 
Various studies have reported multiple potential predisposing factors linked to MTX 
outcome. Most of authors have speculated there are several factors predisposing to 
MTX-related side effects which including demographics factors (age and sex), 
disease specific factors (disease duration and severity) and concomitant drugs 
(Romão et al., 2014). An evidence has indicated advanced age of RA patient 
concurrent with renal failure increase a risk of MTX toxicity (Jerzy and Jacek, 2008). 
Besides that, RA patients concomitant on other medication like steroids, NSAIDs 
and other DMARDs were at higher risk of developing MTX-related side effects. 
Since administration of folic acid is crucial to alleviate the side effects, therefore lack 
of folic acid supplementation will increases the risk of hepatotoxicity and GIT 
intolerance (Report, 2003). The limited literature described the influence of MTX 
dosage on the development of MTX-related side effects. Some studies found high 
MTX dose and cumulative dose linked to development of non-alcoholic liver disease 
(NAFLD) and elevated transaminase with unknown underlying mechanism (Hyrich, 
2012; Sakthiswary et al., 2014). 
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Genetic variation encoded within MTX metabolism is the most prominent genetic 
factors associated with MTX toxicity and efficacy. However, due to discrepancy of 
findings among published studies, no accurate genetic predictive markers for MTX 
toxicity have been identified so far. Hence, the current study intended to investigate 
the impact of selected SNPs in genes encoded in folate metabolic pathway and drug 
transport protein in development of MTX adverse effects. Genetic polymorphism in 
Dihydrofolate reductase (DHFR) enzyme and Solute carrier family 19 folate 
transporter member 1/Reduced folate carrier-1 (SLC19A1/RFC-1) are the potential 
genetic markers that associated with MTX toxicity. Many of studies showed both 
SNPs of DHFR (rs12517451) and SLC19A1 (rs1051266) were significantly 
associated with MTX-related side effects (Grabar and Lestan, 2008, Owen et al., 
2013). Moreover, to best of our knowledge, there are no genetic study has reported 
from Malaysia, which has explored the influence of variants in DHFR and SLC19A1 
on MTX toxicity.  
 
Besides that, the findings from this study also will assist the development of 
personalized therapy which is one of the main goals of modern medicine. In addition, 
this study also possibly discovered the potential pathophysiological explanation 
about studied gene in order to elucidate the underlying mechanism of MTX toxicity. 
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1.3 Objectives of the research 
 
1.3.1 General Objective  
 
To evaluate the association between genetic polymorphism, clinical factors and 
methotrexate-related side effects among RA patients from HUSM, Kelantan. 
 
1.3.2 Specific Objectives 
 
1. To determine the prevalence of the most commonly observed side effects of MTX 
among RA cases by retrospective examination of patient clinic files and medical 
report. 
2. To assess the association between DHFR rs12517451 and SLC19A1 rs1051266 
variants with MTX-related side effects by using Restriction Fragment Length 
Polymorphism (RFLP) method.  
3. To determine the extent by which factors (demographic factors, clinical variables 
and genetic variants) contribute to the risk of MTX-related side effects in the RA 
patients by logistic regression of data generated 1 and 2 above. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 Rheumatoid Arthritis (RA) 
2.1.1 Epidemiology of RA  
The considerable variation in prevalence and incidence of RA has been reported 
from various studies indicated the distribution of disease was widely vary across 
different populations (Alamanos and Drosos, 2005). The majority of studies on 
prevalence and incidence of RA that have been conducted among North Europe and 
North American population has shown the prevalence of 0.5- 1.1% .This also 
demonstrate the incidence rate of RA at this region which ranged from 20 to 50 cases 
per 100,000 populations (Alamanos, Voulgari and Drosos, 2006). The prevalence 
and incidence of RA in South East Asian region has been reported the lowest so far.  
The highest prevalence of RA in 2006 has was reported from India with 0.5%, 
followed by China (Beijing) 0.34%, Indonesia (urban) 0.3%, Japan 0.3%, Vietnam 
0.28%, Philippines (urban) 0.17%, Malaysia 0.15% and Thailand 0.12% (Davatchi, 
2006). The lowest frequency of RA was found in some areas of rural Africa (Silman 
and Pearson, 2002). In fact, RA occurs at twice the rate in women compared with 
men, with a prevalence of 1.06% in women compared with 0.61% in men (Rudan et 
al., 2015). 
 
The differences of prevalence and incidence of RA across different population can be 
explained by certain potentials predisposing risk factors of RA such as genetic and 
environmental factors that influence susceptibility towards development of disease. 
Besides that, the method identification for diagnosis of RA also has contributed this 
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variation. The higher mortality rate of RA patients has been reported due to 
decreasing life span in RA patients (Gabriel et al., 2003). By treating RA patients 
with anti-rheumatic drugs, the treatment only manage the symptoms of RA which 
relate to lowering a person lifespan. However, this expected survival of RA patients 
also might depend on severity of the disease and the disease duration (Alamanos, 
Voulgari and Drosos, 2006).  
 
2.1.2 Pathogenesis of RA 
The precise mechanism for initiation of RA is still unknown. It was speculated that 
the initiation of this disease was due to production of autoantibodies against specific 
citrullinated proteins (ACPA) and activation of innate immunity. It has been known 
the detection of rheumatoid factor (RF) is predictive markers to identify patients with 
rheumatoid arthritis. Nowadays, a new alternative predictive marker has been 
discovered. Anti-citrullinated protein antibodies (ACPAs) is a new potential marker 
to detect the disease activity. It has been found in almost 50% of RA patients which 
may facilitate for identification of patients with early arthritis (Arend and Firestein, 
2012).  
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Figure 2.1: The prevalence of rheumatoid arthritis worldwide (Cross et al., 2014).  
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The mechanism of initiation of RA is known to be related to stimulation of immune 
cells and inflammatory events. Initially, innate immune system is stimulated by 
several initiating agents including pathogenic microorganism, toll like receptor 
(TLR) or environmental factors, in which subsequently activate various immune cells 
such as mast cells, neutrophils, dendritic cells and possibly chondrocytes. The 
production of ACPAs in many mucosal-lined organs was occurred in response to 
inflammatory cytokines. ACPAs, the specialized antibody towards is circulated 
within synovial tissues, it will bind to specific epitope in cartilage and synovial that 
leads to destruction of cartilage components and other synovial tissues through 
formation of complement cascade pathway (Komatsu and Takayanagi, 2012). The 
damage in synovial tissue is also related to higher expression of pro-inflammatory 
cytokines especially tumor necrosis factor (TNF) and IL-6 that result in proliferation 
of synovial cells in joints and formation of pannus which cause the destruction of 
cartilage and bone erosions (Wasserman, 2011). Moreover, activation of helper CD4
+
 
T-cells, specifically Helper T (Th17) cells, also plays a major role in initiation of 
immune response in RA.  
 
2.1.3 Risk Factors of RA 
RA is known as multifactorial disease that result from interaction between genetic 
and environmental factors (Tobon, Youinou and Saraux, 2010). Several risk factors 
of RA that has been proven by various studies linked to disease such as genetic 
variants encode for the functional of immune systems, smoking, anti-citrullinated 
protein antibodies (ACPAs) and rheumatoid factors (RF).  
 
 
11 
 
2.1.3.1 Genetic risk factor  
Until now, researchers are still uncertain whether the impact of genetic factors can be 
linked with risk of RA or the severity of the disease or both of them. In development 
of RA, the genetic variant in MHC and non-MHC genes is believed associated with 
immune response and inflammation. Class II region of MHC locus was the most 
prominent genetic risk that linked to RA, specifically genes encoding HLA-DR 
molecules. The association between different HLA DRB1 alleles and risk to RA have 
been demonstrated in several population groups. Besides that, the “shared epitope” 
(SE) is the conserved 5 amino acid sequence found in HLA DRB1 alleles and also 
other variety of alleles play an important role in pathogenesis of RA. Vast majority 
of RA patients carried shared epitope were associated other variety autoimmune 
disorder (Konda Mohan, Ganesan and Gopalakrishnan, 2014). 
 
Various genes of non-MHC molecule also linked to RA. The most prominent non-
MHC gene is a single nucleotide polymorphism in the gene PTPN22 which relatively 
can be found in many populations. The presence of PTPN22 allele has been showed 
increase risk of development of RA. If fact, least frequent of Asian populations have 
detected with PTPN22 polymorphism, thus this allele may only partly explained the 
occurrence of RA among Asian. Whereas, those individuals from other populations 
present with PTPN22 polymorphism have greater risk of RA development. The 
association between PTPN22 polymorphism and expression ACPAs has been 
described (Begovich et al., 2004). 
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Furthermore, there are also other several of non-MHC genes have been studied 
which related to risk of RA and other autoimmune disease, including STAT4 (T-cell 
response), TNFAIP3 (TNF protein, cytokine), CCR6 (chemokine receptor) and 
CD40 (B cells, monocytes and DCs) (Silman and Pearson, 2002; Wasserman, 2011). 
Even though lack of evidence regarding the role of genetic factors in the occurrence 
of RA, it may possibly explain the significant variation in prevalence and incidence 
of RA among different populations and ethnic groups. 
 
2.1.3.2 Gender and Hormonal Factors 
Commonly, women are two times likely diagnosed with RA compared to men. This 
can be explained why the incidence of RA in women was higher than in men (Rudan 
et al., 2015). Some of studies have speculated hormonal imbalance and pregnancy 
are major factors contribute to increase risk of RA in females (Alamanos and Drosos, 
2005; Silman and Pearson, 2002).  
 
Many of studies have found the influence of exogenous hormone may correlate with 
risk of RA. The follow-up study has discovered the women who taking oral 
contraceptive pill have low incidence of RA. However, no clear explanation was 
found. They have speculated oral contraceptive pill might able to reduced risk of RA 
and provide a protective effects against the development of disease, or maybe it just 
delay the disease progression (Silman and Pearson, 2002). Moreover, women who 
are undergo hormone replacement therapy (HRT) may have lower risk of RA. HRT 
has been shown possess protective effect against the development of RA by 
preventing the production of ACPAs with unknown underlying mechanism (Salliot 
et al., 2010).  
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2.1.3.3 Ethnicity 
The differences in prevalence and incidence of RA among different populations or 
ethic groups have been described.  Some ethic and racial groups are at higher risk for 
RA than others. Ethnicity was considered as independent risk factor which involved 
between the interaction of genetic and environmental factors. Comparison of 
population with similar genetic backgrounds but different lifestyles clearly explained 
about the influence of non-genetic factors.  Genetic variation associated with 
pathogenesis of RA possibly demonstrated the significant different of risk and 
severity of RA among ethic groups (Silman and Pearson, 2002). 
 
2.1.3.4 Environmental Factors 
There are several environmental factors linked to risk of RA including smoking, 
infections, dietary factors and pollutants. Long term exposure to these predisposing 
factors may promote the development of disease until it was clinically apparent. 
 
Smoking  
The effect of smoking to risk of RA has been reported in various studies. Smoking 
has showed an increase risk of RA especially in those who are carried the “shared 
epitope”. An evidence has showed smoking can promote the expression of RF and 
ACPAs production, which explained the higher risk of RA in individual having 
“shared epitope” (Stolt, 2003).  
 
Tetrachlorodibenzo-P-dioxin (TCDD) is one of the harmful chemical in cigarettes, 
which is believed to play a role in pathogenesis of disease. TCDD binds to 
arylhydrocarbone receptor and regulates the expression of several cytokine such as 
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IL-1β, IL-6, IL-8 through extracellular signal-regulated kinase signalling cascades 
(Kobayashi et al., 2008). In addition, synergistic interaction between polymorphism 
of PTPN22 genes and heavy smoking towards the risk of RA also has been reported 
(Begovich et al., 2004). 
 
Infection 
Several potential infectious agent may implicated to RA development such as Human 
parvovirus B19, rubella virus, human retrovirus 5 and Epstein-Barr virus (EBV) have 
been identified (Silman and Pearson, 2002; Tobón, Youinou and Saraux, 2010). The 
presence of viral genome, specific antigens and antibodies production are indicator to 
determine infected individual with RA.  The detection of high level of EBV antigens 
and production antibodies against latent and replicative virus has been found in some 
RA patients. Besides that, the presence of EBV RNA in B cell of synovial fluids was 
strongly indicated integration of EBV viral genome may trigger for RA development. 
Other viral DNA of pathogenic microorganism such as parvovirus B19 also have 
been found in synovial tissue and cells of RA patients (Tobón, Youinou and Saraux, 
2010).  
 
Dietary Factors 
Dietary intake is important factors determine the susceptibility one individual 
towards various illnesses. The consumption of food rich with omega 3 fatty acids and 
vitamin D such as fish, olive oil and cooked vegetables able to protect individual 
from occurrence of RA. Eicosapentaenoic acid is one of omega 3 fatty acids is 
responsible for anti-inflammatory effect by competing with arachidonic acid to 
reduce inflammatory response in RA (Ariza-Ariza, Mestanza-Peralta and Cardiel, 
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1998). Besides that, vitamin K is also another important nutrient mainly found in 
various vegetables able to alleviate inflammatory response in RA by inhibiting the 
proliferation of fibroblast-like synoviocytes, specialized cells involve in pathogenesis 
of chronic inflammatory disease (Silman and Pearson, 2002).   
 
2.2 Drug Modifying Anti Rheumatic Diseases (DMARDs) 
2.2.1 Overview  
Nowadays, we are still unable to find a cure for RA. Usually, RA patients were 
treated with variety of drugs including glucocorticoids and drug-modifying anti-
rheumatic diseases (DMARDs). The current treatment was seen to alleviate the 
symptom and improves the disease progression.  
 
DMARDs are the group of medication that commonly used for treatment in patients 
with rheumatoid arthritis and management of other inflammatory arthritis. There are 
few types of DMARDs which include (1) conventional synthetic DMARD 
(csDMARDs) (methotrexate (MTX), cyclosporine, azathioprine, sulfasalazine and 
hydroxychloroquine), (2) biologic DMARDs (bDMARDs) (Infliximab, Etanercept, 
Adalimumab, and Rituximab), (3) biosimilars DMARDs (bsDMARDs) and (4) 
targeted synthetic DMARDs (tsDMARDs) (Singh et al., 2012). The main function of 
synthetic DMARDs is to subdue the autoimmune response while the biological 
DMARDs was acting on individual molecules to inhibit the production and 
expression of inflammatory mediators such as TNF, IL-1, and IL-6 (Umićević 
Mirkov and Coenen, 2013). Even though biological DMARDs is more efficient 
compared to synthetic DMARDs, the application of these drugs as first-line 
treatment in clinical practice was limited due to much higher cost required. The use 
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of biological DMARDs was commonly implied to those patients fail to respond with 
DMARDs monotherapy or sometimes combination with other conventional 
DMARDs (Choy et al., 2005). 
 
The list of common prescribed cDMARDs for treatment of RA are including 
methotrexate (MTX), leflunomide, sulfasalazine, hydroxychloroquine, and 
azathioprine (Singh et al., 2012). However, MTX is the first choice for RA treatment 
because of its established efficacy and affordability compared to others (Owen et al., 
2012).  Currently, this drugs also widely used in other related-arthritis disorder such 
as ankylosing spondylitis, psoriasis, and systemic lupus erythematosus. In 
rheumatoid arthritis disease, mechanism of action of MTX is mainly to alleviate pain 
and inflammation as well as to prevent joint damage by sustaining the structure and 
function of joint. 
 
2.2.2 Methotrexate (MTX) as First-line of Treatment in RA 
Methotrexate (4-amino-4deoxy-N
10
-methyl-pteroyl-L-glutamic acid) is known as 
antimetabolite agents that structurally similar to folic acid  (Bannwarth et al., 1996). 
It has been synthesized in 1948 and initially introduced as an anticancer agent 
(Braun, 2011). A few years later, MTX was started use as primary treatment for RA 
after rheumatologist has discovered significant improvement in RA patients who are 
taking MTX. Until now, MTX is used as first-line therapy for most of patients with 
RA. The primary role of MTX is to alleviate symptoms of disease and prevent the 
progression of joint damage (Griffiths H et al., 2014).  
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As many other DMARDs have been used in treating RA, MTX is most well tolerated 
with considerable toxicity profile. Gastrointestinal toxicity is the most common 
MTX-related side effect present in RA patients. Rare side effects are  bone marrow, 
lung or liver toxicity (Weinblatt, 2013). Comparison of MTX with other DMARDs 
suggested that MTX therapy exhibit more reliable improvement in disease activity of 
RA patients. The 52 weeks randomized double-blind trial that evaluating the efficacy 
of MTX and leflunomide (LEF) has found group of patients on MTX therapy has 
greater improvement in disease activity than patients on leflunomide alone. 
Compared to MTX, many of RA patients on azathioprine had withdrawn from 
treatment due to lack of efficacy and adverse effects (Braun, 2011). Besides that, 
even though advanced of complex biological DMARDs has been develop recently, 
MTX still remained as anchor drugs in majority of patients with RA. This may 
explain why the combination of anti-TNF therapy with MTX is far more effective as 
compared to anti-TNF alone (Griffiths H et al., 2014).  
 
Despite the long establishment of MTX as gold therapy of RA, the optimum dosage 
for every individual patient is still an issue. Commonly, rheumatologist will prescribe 
MTX to patients at a starting dose of 7.5-10 mg weekly either orally or by 
subcutaneous injection. The increase of dose at 5 mg per month is required for 
patients who are did not show good improvement in disease activity. However, 
escalation of dosage was only tolerated until 25-30 mg weekly as higher dose can 
lead to drug toxicity (Griffiths H, 2014).  
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2.2.3 Mechanism of Action of MTX 
The precise mechanism of action of MTX is still poorly understood. MTX is an 
active drug that is a highly selective competitive inhibitor of dihydrofolate reductase 
(DHFR). DHFR is enzyme crucial in catalyzes the conversion of dihydrofolate to 
tetrahydrofolate which is active cofactor involved in the de novo synthetic pathway 
for purine and pyrimidine of DNA and RNA required for cell proliferation. As MTX 
primarily supress the function of DHFR, it also acts on another various key enzymes 
in folate metabolic pathway (Swierkot and Szechinski, 2006).  
 
Figure 2.2 shows the mechanism of MTX in mammalian cells. MTX mainly enter 
cells by active transport mechanism via drug transport protein, namely reduced folate 
carrier (RFC) or also known as SLC19A1. Within the cell, MTX is converted into 
polyglutamate form (MTX-PG) by the enzyme folypolyglutamate synthase (FPGS). 
Polyglutamation is process addition of glutamic acid moieties by FPGS enzyme to 
form an activated MTX. MTX-PG can be hydrolysed by enzyme γ-glutamyl 
hydrolase (GGH) and transported out cells by ATP-binding cassette (ABC) protein 
transport (Griffiths H, 2014). Within the cells, MTX-PG will bind to and inhibit 
several important enzymes crucial in biochemical of cell growth including DHFR, 
thymidylate synthase (TYMS) and 5-aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) transformylase (ATIC). Pyrimidine biosynthesis was suppressed due to 
inhibition of TYMS by MTX-PG, an essential enzyme for conversion 
deoxyruridylate to deoxythymidylate.  
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The inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
transformylase (ATIC) was result in increasing intracellular adenosine levels which 
appears to be the mechanism for anti-inflammatory activity of methotrexate (Stamp 
and Roberts, 2011). The activation of adenosine receptors through the binding of 
adenosine subsequently inhibits the production of pro-inflammatory cytokines 
involved in RA development such as TNF-α, interferon-γ and IL-1β (Cronstein, 
2005; Stamp and Roberts, 2011). MTX-PG also indirectly inhibit 5,10-methylene-
tetrahydrofolate reductase (MTHFR) which key enzyme in folic acid pathway and 
responsible for the conversion of 5,10-,ethylene THF to 5 methyl-THF in process of 
rementhylation of homocysteine to methionine (Ranganathan, 2008). Other putative 
mechanisms are including increase apoptosis of T cells, alteration of expression of 
cellular adhesion molecules, reduction in expression of cellular adhesion molecules 
and anti-angiogenesis. However, it was speculated that the anti-inflammatory activity 
mediated by release of adenosine is probably more important than the anti-
proliferative effects (Hyrich, 2012) 
 
2.5 The Development of MTX-related side effects (AEs) 
2.5.1 Prevalence and incidence of MTX-related side effects in RA patients 
 
RA patients treated with MTX are more likely to withdraw from therapies due to 
adverse effects rather than lack of efficacy. For instance, a double-blind randomized 
clinical trial study has demonstrated that 15% of RA patients were withdrawn from 
MTX therapy due to side effects while only 3% of them stop taking MTX as first-
line treatment due to inefficacy of drug (Ishaq et al., 2011). Usually, adverse effects 
of low-dose MTX are mild, self-limited and preventable. However, some of patients 
may expose to other severe or life-threatening type of adverse effects which required 
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drug discontinuation (Tian, Henghe, Cronstein, 2007). During the last two decades, 
numerous epidemiological studies have been established on the efficacy and side 
effects of MTX therapy. The reported prevalence of MTX-related side effects 
worldwide ranges from 30% to 80% of patients. According to published studies, 
overall data regarding prevalence of MTX-related side effects among Asians and 
Caucasians patients showed approximately more than half of RA patients on MTX 
were likely to suffer from one or more adverse effects. 
 
Among Asian population, the wide variation in prevalence of MTX adverse effects 
was reported by numerous studies. On the basis of retrospective and prospective 
cohort studies, the prevalence of MTX-related side effects in Asian population 
ranged between 20% and 80% of patients. Specifically, the prevalence of MTX-
related side effects observed within patients of East Asia was 50% in China (Xiao et 
al., 2010), 38% in Japan (Fujii et al., 1997), 40% in Korean (Kim et al., 2006) and 
25% in Taiwan, whereas among patients of South Asia were 20% in India (Atic, 
Muralidharan and Jain, 2016) and 80% in Pakistan (Ishaq et al., 2011). A 
Singaporean study also reported the incidence of MTX associated-liver toxicity and 
Non-alcoholic Fatty Liver Disease (NAFLD) was 11.4% and 4.6% in patients 
respectively (Sakthiswary et al., 2014). The variation in data indicated ethnicity may 
affect the development of MTX-related side effects. 
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Figure 2.2: The diagram above show a complete cellular pathway of methotrexate 
within the mammalian cells. 5,10-CH2-THF: 5,10-methylene tetrahydrofolate; 5-
CH3-THF: 5-methyl tetrahydrofolate; AICAR: 5-aminoimidazole 4-carboximade 
ribonucleotide; ATIC: AICAR formyltransferase; FAICAR: 10-formyl AICAR, FH2 
: dihydrofolate; MTX-PG : Methotrexate polyglutamate (Ranganathan et al, 2008). 
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2.5.2 Mechanism of action of MTX toxicity 
The exact mechanism of MTX toxicity is still obscure. Mostly overall side effects 
have been directly related to MTX involvement in the previously mentioned 
metabolic pathways (van Ede et al., 1998). The inhibition of various folate 
metabolizing enzyme and other folate-related pathway by MTX may partly explain 
the occurrence of adverse effects in RA patients. The anti-proliferative activity of 
MTX associated with depletion of purines, thymine and methionine that crucial in 
cell growth mainly affected by rapidly dividing tissue such as bone marrow and 
gastrointestinal tract. Different type of adverse effects can be related to various MTX 
metabolic pathways. The toxicities from folate antagonism, including anemia, 
neutropenia, stomatitis and oral ulcers can be prevented or alleviated by folic acid 
supplementation. On the hand, prescribing physician should aware of toxicities 
unrelated to suppression of folate metabolisms such as MTX-induced nodulosis, 
hepatic fibrosis, pulmonary fibrosis, lethargy, fatigue, and renal failure (Tian, 
Henghe, Cronstein, 2007). 
 
The expression of intracellular adenosine by MTX acting on 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) transformylase (ATIC), the folate 
metabolizing enzyme was the main mechanism related to its anti-inflammatory 
action in RA patients (Cronstein, 2005). Many of studies have intended to investigate 
the putative role of adenosine pathway as potential mechanism involved in MTX 
toxicities (Tian, Henghe, and Cronstein, 2007). An in vitro study had shown purified 
monocyte treated with methotrexate has formed a multinucleated giant cell. This was 
indicated the possible mechanism of MTX-induced nodulosis present in RA patient.  
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Besides that, the adenosine pathway also associated with the development of MTX-
induced hepatic fibrosis. Hepatoma cells that treated with methotrexate also lead to 
increase of adenosine production. Another in vivo study also has found the higher of 
adenosine level in mice treated with hepatotoxin, an adenosine agonist that binding 
to adenosine A2A receptor. This result demonstrated the role adenosine A2 receptor 
may involve in pathogenesis of hepatic fibrosis (Chan and Cronstein, 2010; Tian, 
Henghe, and Cronstein, 2007). Moreover, the effect ethanol stimulates the release of 
adenosine by hepatocytes was also well documented. Thus, this evidence has shown 
alcohol consumption in MTX-treated patients will likely increase the likelihood of 
developing liver cirrhosis (Swierkot and Szechinski, 2006). 
 
The occurrence of MTX toxicity is also associated with homocysteine-methionine-
polyamine pathway. In the homocysteine and methionine pathway, MTHFR enzyme 
plays an important role in conversion of homocysteine to methionine. Inhibition of 
MTHFR enzyme through indirect effect of MTX will result in elevated level of 
homocysteine in the plasma. The accumulation of homocysteine level will lead to 
increased risk of various disorders such as vascular and neurodegenerative diseases, 
autoimmune disease, osteoporosis and cancer (van Ede et al., 1998). However, no 
plausible explanation regarding the deleterious effect hyperhomocysteinemia 
associated with MTX toxicity has been discovered yet. A study has found those 
patients present with GIT toxicity had a significantly higher level of homocysteine 
after 52 weeks of MTX treatment. In addition, the interference of MTX in 
homocysteine-methionine pathway also will result in decreased level of SAM and 
SAH, which is a marker of methylation reactions. Diminished level of SAM and 
SAH might explain the development of adverse effect in some RA patients treated 
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with MTX. Finally, the inhibition of polyamine synthesis by MTX also may cause 
toxicity, because polyamines are important for cell function (van Ede et al., 1998). 
 
2.5.3 Specific MTX related side effects 
Recently, a considerable literature has grown up around the theme of safety among 
MTX users. Methotrexate related adverse effects (AEs) can be defined as one or 
combination of the following side effects including nausea/vomiting, abnormal liver 
function (greater than twice the upper limit of normal values), aggravated skin 
nodules, oral ulcers and cytopenia or any other known MTX related AE documented 
in drug literature (Ghodke et al., 2008). Usually, RA patients would start to 
experience low dose of MTX-related side effects within first 6 months of therapy 
(Mittal et al., 2012).  
 
2.5.3.1 GIT toxicity  
Gastrointestinal (GIT) toxicity/intolerance is the most frequently observed in RA 
patients on MTX and this accounted for more than half of overall side effects (Xiao 
et al., 2010; Muralidharan et al., 2015). The reported side effects included a range of 
GIT toxicity symptoms like abdominal pain, vomiting, diarrhea, nausea, and 
dyspepsia (Patil et al., 2014). Previous studies have shown GIT toxicity was 
commonly present in obese patients and those previously diagnosed with GIT 
adverse effects (Hoekstra et al., 2003; Report, 2003). The highest rate of GIT toxicity 
among RA patients can be explained presumably due to the primary effects of MTX 
on rapidly dividing mucosal cells lining the GI tract (Kremer, 2004; J., 2008). 
However, the causes of GIT toxicity also might be associated with other predisposing 
factors such as concomitant drugs especially NSAIDs. Several studies have 
